Juvena Therapeutics closes $33.5M Series B led by Bison Ventures with Eli Lilly partnership

Juvena Therapeutics/JUV-161

Juvena closed a $33.5 million Series B led by Bison Ventures, with participation from Eli Lilly, Jefferson Life Sciences, Mubadala Capital, and Manta Ray. The Series B advances clinical programs for JUV-161 (muscle regeneration) and JUV-112 (obesity). Separately, the company has a $650 million research collaboration agreement with Eli Lilly covering muscle health and body composition targets.